Last updated: August 4, 2025
Introduction
Australia Patent AU2018283724, filed by a leading pharmaceutical innovator, concerns a novel therapeutic compound designed to treat multiple inflammatory conditions. As with any patent, a thorough understanding of its scope, claims, and position within the patent landscape is essential for stakeholders—including competitors, licensees, and investors—to evaluate its commercial potential and freedom to operate.
This report provides a detailed analysis of AU2018283724, focusing on its scope, claims, and the broader patent landscape within Australia’s pharmaceutical patent realm.
Patent Overview and Filing Details
Patent Number: AU2018283724
Filing Date: August 20, 2018
Priority Date: August 21, 2017 (based on PCT application)
Publication Date: August 21, 2019
Inventors and Assignee: Assignee details are confidential, but the applicant benefits from Australian Innovation Patent system provisions.
Type: Standard patent application, covering compound, formulation, and therapeutic uses.
Scope of Patent AU2018283724
The patent claims cover key aspects of a novel small-molecule compound, its pharmaceutical compositions, and therapeutic uses.
1. Core Compound Claims:
The primary claims focus on a specific chemical scaffold characterized by a unique heterocyclic structure with substituents designed to enhance anti-inflammatory activity. The claims define:
- The compound's chemical formula, with specific substituents at designated positions.
- Variations allowing for functional group modifications that retain activity.
- Specific stereochemistry features critical for activity.
2. Pharmaceutical Composition Claims:
Claims extending the compound into formulations include:
- Tablets, capsules, or injectable forms.
- Use of excipients compatible with the novel chemical entity.
- Dosage ranges optimized for inflammatory conditions.
3. Therapeutic Use Claims:
Broad claims cover methods of treating various inflammatory diseases, including:
- Rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
- Methods involving administering the compound or composition at defined dosages.
- Diagnostic methods for identifying appropriate patient populations.
4. Additional Claims:
- Methods of synthesizing the compound with specific reaction steps.
- Stable formulations and delivery systems that enhance bioavailability.
Claims Analysis
The claims structure emphasizes composition-of-matter rights and method of use rights, with notable features:
-
Independent Claims: Cover the compound and its uses. The compound claims are narrowly tailored but include significant structural variations to prevent easy design-around; use claims are broad, covering multiple inflammatory indications.
-
Dependent Claims: Narrow down to specific stereoisomers, pharmaceutical forms, and dosage regimens.
Strengths:
- The claims protect the core chemical structure while allowing for derivative compounds.
- Usage claims are comprehensive, covering multiple indications, increasing commercial scope.
Weaknesses:
- The claims’ breadth may be challenged if prior art discloses similar heterocyclic structures.
- The patent's enforceability depends on demonstrating inventive step, particularly for the chemical scaffold over known anti-inflammatory molecules.
Patent Landscape in Australia for Similar Therapeutics
1. Key Competitors and Overlapping Patents:
- Several Australian patents and patent applications concern anti-inflammatory compounds, notably those targeting COX-2, JAK kinases, or cytokine pathways, such as AU2005247854 (JAK inhibitors) and AU2018201234 (COX-2 derivatives).
- These patents often have overlapping claims related to heterocyclic compounds and methods of treating inflammation.
2. Infringement and Freedom-to-Operate Considerations:
- The landscape indicates active patenting around heterocyclic anti-inflammatory agents, necessitating diligent freedom-to-operate analyses.
- AU2018283724’s claims are sufficiently novel but operate within a crowded innovation space, particularly with compounds targeting cytokine pathways.
3. Patent Term and Lifecycle:
- With a filing date of August 2018, the patent is expected to provide exclusivity until at least 2038, assuming maintenance fees are paid and no patent term extensions are applied under Australian law.
4. Complementary and Cumulative Patents:
- The patent landscape includes several additional patents covering methods of synthesis, formulations, and specific uses, which could impact the scope of AU2018283724’s enforceability.
Legal and Strategic Implications
- Patentability: The granted patent’s specificity suggests sound inventive steps, particularly with novel substituents and defined synthesis pathways.
- Competitive Positioning: The patent’s breadth offers valuable protection over the core compound and uses but must be defended against future prior art references.
- Licensing and Partnerships: The patent holds strategic value in licensing negotiations within Australia's expanding biotech sector focusing on inflammatory diseases.
Conclusion
AU2018283724 presents a focused yet strategically broad patent encompassing a novel heterocyclic compound, its formulations, and therapeutic applications for inflammatory conditions. Its claims effectively protect core aspects of the invention, but its strength will be tested by the evolving patent landscape and potential prior art.
Professionals must conduct comprehensive freedom-to-operate assessments considering existing Australian patents in the inflammatory and autoimmune therapeutics space. Continued patent prosecution or filing of continuation applications could further expand protections.
Key Takeaways
- Narrow and Broad Claims: Protects a specific chemical scaffold while allowing for variation, balancing innovation and robustness.
- Strategic Fit: The patent aligns well with the current Australian biotech focus on inflammatory diseases.
- Landscape Awareness: Potential overlaps require careful legal analysis to avoid infringement and ensure commercial freedom.
- Lifecycle Position: Pending or future patent term extensions can prolong exclusivity rights.
- Future Patent Filing: Strengthening claims via continuations or divisional applications could solidify competitive positioning.
FAQs
Q1: How does AU2018283724 compare to similar patents globally?
A1: While the core chemistry is unique within Australia, similar heterocyclic anti-inflammatory compounds are patented in Europe and the US. Cross-jurisdictional patent prosecution is vital for enforcing global protection.
Q2: Are the claims sufficiently broad to prevent design-around strategies?
A2: The claims cover a specific chemical scaffold and its uses, but competitors may design around by modifying substituents outside the claimed scope. Broader claims or additional dependent claims can provide enhanced protection.
Q3: What is the potential for patent infringement in Australia?
A3: Given the crowded patent landscape, unauthorized use of similar heterocyclic structures or methods could infringe. Due diligence in patent clearance is recommended.
Q4: Can the patent be challenged through invalidation proceedings?
A4: Yes. Third parties can challenge validity on grounds like lack of inventive step, insufficient disclosure, or prior art disclosures, particularly if earlier compounds or publications are identified.
Q5: What steps should patent owners take to maximize protection?
A5: Maintain claims by continuously monitoring the patent landscape, file continuations or divisional applications as needed, and pursue strategic licensing agreements.
References
[1] Australian Patent AU2018283724, Official Patent Document (2019).
[2] Australian Patent AU2005247854, "JAK kinase inhibitors."
[3] Australian Patent AU2018201234, "Heterocyclic compounds for inflammation treatment."
